[Brucella bacteremia reactivation 70 years after the primary infection]

Med Mal Infect. 2010 Apr;40(4):238-40. doi: 10.1016/j.medmal.2009.08.005. Epub 2009 Sep 26.
[Article in French]

Abstract

After primary infection, some bacteria can remain in a latent state for several years before a new bacteremia, often due to a weakened immune status. This is common for Mycobacterium tuberculosis, less for other pathogens more difficult to have in mind when facing patients with fever. We report the case of an 84-year-old female patient presenting with fever in the months following antilymphoma chemotherapy, due to bacteremic brucellosis (with a hemophagocytic syndrome) probably latent after primary infection as a child.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged, 80 and over
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bacteremia / complications
  • Bacteremia / drug therapy
  • Bacteremia / physiopathology*
  • Bacteremia / therapy
  • Brucella melitensis*
  • Brucellosis / complications
  • Brucellosis / drug therapy
  • Brucellosis / physiopathology*
  • Brucellosis / therapy
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Doxycycline / therapeutic use
  • Drug Therapy, Combination
  • Female
  • France
  • Humans
  • Immunocompromised Host
  • Immunoglobulins, Intravenous / therapeutic use
  • Lymphoma, Non-Hodgkin / complications
  • Lymphoma, Non-Hodgkin / drug therapy
  • Recurrence
  • Rifampin / therapeutic use
  • Rituximab
  • Spain / ethnology
  • Time Factors
  • Vidarabine / administration & dosage
  • Vidarabine / adverse effects
  • Vidarabine / analogs & derivatives

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunoglobulins, Intravenous
  • Rituximab
  • Cyclophosphamide
  • Vidarabine
  • Doxycycline
  • fludarabine
  • Rifampin